Assuntos: IMUNOGENÉTICA, COVID-19, VACINAS VIRAIS
ABNT
PEREIRA, Rosa Maria Rodrigues et al. Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose. Clinics, v. 78, 2023Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/52881. Acesso em: 22 ago. 2024.APA
Pereira, R. M. R., Dagostin, M. A., Caparbo, V. F., Sales, L. P., Pasoto, S. G., Silva, C. A., et al. (2023). Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose. Clinics, 78. doi:10.1016/j.clinsp.2022.100150NLM
Pereira RMR, Dagostin MA, Caparbo VF, Sales LP, Pasoto SG, Silva CA, Yuki EFN, Saad CGS, SHINJO SK, BONFA E. Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose [Internet]. Clinics. 2023 ; 78[citado 2024 ago. 22 ] Available from: https://observatorio.fm.usp.br/handle/OPI/52881Vancouver
Pereira RMR, Dagostin MA, Caparbo VF, Sales LP, Pasoto SG, Silva CA, Yuki EFN, Saad CGS, SHINJO SK, BONFA E. Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose [Internet]. Clinics. 2023 ; 78[citado 2024 ago. 22 ] Available from: https://observatorio.fm.usp.br/handle/OPI/52881